Copy

Click here if you cannot read this message

  Press Release 24 May 2019  
 
 
 


Bone Therapeutics to present data at TERMIS European Chapter Meeting 2019

 

Gosselies, Belgium, 24 May 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that the Company will present on 29 May at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) European Chapter Meeting 2019 in Rhodes, Greece.
 
TERMIS is a not-for-profit Society with three chapters. TERMIS is the most prominent organisation in the field of tissue engineering and regenerative medicine globally. TERMIS promotes education, research, innovation, clinical translation and social responsibility within the field of tissue engineering and regenerative medicine through regular meetings, training courses, scientific and lay publications, outreach activities and other forms of communication. TERMIS also provides an international forum for the informed discussion of challenges and achievements of tissue engineering therapies.
 
In the oral presentation, the R&D team of Bone Therapeutics will present preclinical in vitro and in vivo results highlighting the potent osteogenic properties of Bone Therapeutics’ injectable allogeneic bone-forming cell therapy product to promote bone regeneration and improve fracture healing in relevant animal models.

 
 
Presentation Details:
 
Title: Injectable bone-forming cells derived from human BM-MSC improve bone repair in a mouse model by promoting host and donor bone formation through two mechanisms of action 
Authors: Delphine De Troy 1, Laure Hertzog 1, Sylvain Normand 1, Anna Tury 2, Roland Baron 3, Sandra Pietri 1
Session: S71 - Bone
Session date: Wednesday, 29 May 2019
Session time: 13:00-14:30 CEST (14:00-15:30 EEST)
Location: “Salon des Roses B” room, Rhodos Palace Convention Resort, Iraklidon Avenue (Trianton), Ixia P.O. Box 121 85100 Rhodes, Greece



(1 Bone Therapeutics S.A., Gosselies, Belgium, 2 Skeletal Cell Therapy Support S.A., Gosselies, Belgium, 3 Harvard Medical School, Boston, MA, USA)

  
 
 
 
 

Le communiqué de presse en français

 
 

 
 

For further information, please contact:

Bone Therapeutics SA

Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Gunther De Backer, Head of Corporate Communications and Investor Relations
Tel: +32 (0) 71 12 10 00
investorrelations@bonetherapeutics.com

For International Media Enquiries
Consilium Strategic Communications

Marieke Vermeersch
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier, Arthur Rouillé and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu

  
 

 
 
Follow us

Click here to unsubscribe
 
 

 
         Fond Européen

Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.

 
 
 
 

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an enhanced viscosupplement, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP portfolio covering nine patent families as well as knowhow. Further information is available at www.bonetherapeutics.com.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

  
Bone Therapeutics S.A. • Rue Auguste Piccard, 37 • 6041 Gosselies • Belgium (Europe) • Phone: +32 (0) 71 12 10 00 • Fax: +32 (0) 71 12 10 01 • www.bonetherapeutics.com